Scienture (SCNX) announced that it has formalized a major commercial Pharmacy Benefit Manager, PBM, led Group Purchasing Organization, GPO, rebate agreement, advancing the process of securing formulary access with health plans covering more than 100 million lives for Arbli Oral Suspension, 10 mg/mL. Additional discussions are underway to further expand both commercial and government coverage for the product.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SCNX:
- Scienture files to sell 2.1M shares of common stock for holders
- Scienture Holdings Completes $3.87 Million Stock Offering
- Scienture prices 3.23M shares at $1.20 in registered direct offering
- Scienture announces shipment of launch quantities of Arbli Oral Suspension
- Scienture files $200M mixed securities shelf